Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 8
Submit an article Journal homepage
319
Views
22
CrossRef citations to date
0
Altmetric
Reviews

New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy

Satomi Onoue University of Shizuoka, School of Pharmaceutical Sciences, Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE) Program, 52 – 1 Yada, Suruga-ku, Shizuoka 422 – 8526, Japan +81-54-264-5633; +81-54-264-5635; [email protected]
,
Shingen Misaka University of Shizuoka, School of Pharmaceutical Sciences, Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE) Program, 52 – 1 Yada, Suruga-ku, Shizuoka 422 – 8526, Japan +81-54-264-5633; +81-54-264-5635; [email protected]
,
Yohei Kawabata University of Shizuoka, School of Pharmaceutical Sciences, Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE) Program, 52 – 1 Yada, Suruga-ku, Shizuoka 422 – 8526, Japan +81-54-264-5633; +81-54-264-5635; [email protected]
&
Shizuo Yamada University of Shizuoka, School of Pharmaceutical Sciences, Department of Pharmacokinetics and Pharmacodynamics, Global Center of Excellence (COE) Program, 52 – 1 Yada, Suruga-ku, Shizuoka 422 – 8526, Japan +81-54-264-5633; +81-54-264-5635; [email protected]
Pages 793-811 | Published online: 28 Jun 2009

Bibliography

  • Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-20
  • Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-32
  • Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94
  • Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3
  • Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56:515-48
  • Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007;12:479-86
  • Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005;25:1084-106
  • Borgstrom L, Asking L, Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int J Clin Pract 2005;59:1488-95
  • Taylor K. Pulmonary drug delivery, Churchill Livingstone, Edinburgh, 2002
  • Purewal TS. Formulation of metered dose inhalers, Interpharm, Illinois, 1998
  • Smyth HD, Hickey AJ. Carriers in drug powder delivery: implications for inhalation system design. Am J Drug Deliv 2005;3:117-32
  • Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008;294:L612-31
  • Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53
  • De Boer WI. Cytokines and therapy in COPD: a promising combination? Chest 2002;121:209S-18S
  • Kuwano K. Epithelial cell apoptosis and lung remodeling. Cell Mol Immunol 2007;4:419-29
  • Blease K, Lewis A, Raymon HK. Emerging treatments for asthma. Expert Opin Emerg Drugs 2003;8:71-81
  • Briggs DD. Chronic obstructive pulmonary disease overview: prevalence, pathogenesis, and treatment. J Manag Care Pharm 2004;10:S3-10
  • Jeffery PK. Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Exp Allergy 1999;29(Suppl 2):14-26
  • Frode TS, Medeiros YS. The puzzle of asthma treatment: animal models to genetic studies. Curr Pharm Des 2005;11:2515-24
  • Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006;368:780-93
  • Nagai H, Teramachi H, Tuchiya T. Recent advances in the development of anti-allergic drugs. Allergol Int 2006;55:35-42
  • Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol 2003;111:S799-804
  • Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007;4:526-34
  • Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6:17-25
  • Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989;96:984-7
  • Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16
  • Barnes PJ. Theophylline for COPD. Thorax 2006;61:742-4
  • Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:320-5; discussion 40-1
  • Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 2003;16:247-77
  • Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-8
  • Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83
  • Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov Today 2007;12:472-8
  • Matera MG, Cazzola M. Ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs 2007;67:503-15
  • Onoue S, Yamada S, Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 2007;28:1640-50
  • Said SI. Vasoactive intestinal polypeptide and asthma [editorial]. N Engl J Med 1989;320:1271-3
  • Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003;63:1973-98
  • Gueders MM, Foidart JM, Noel A, et al. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006;533:133-44
  • Hu J, Van den Steen PE, Sang QX, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480-98
  • Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1:437-46
  • Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008;134:1278-86
  • Rennard SI. Antiinflammatory therapies other than corticosteroids. Proc Am Thorac Soc 2004;1:282-7
  • Cheng J, Grande JP. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med (Maywood) 2007;232:38-51
  • Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008;155:308-15
  • Hasko G, Linden J, Cronstein B, et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70
  • Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151S-5S
  • Adcock IM, Chung KF, Caramori G, et al. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006;533:118-32
  • Gonsiorek W, Fan X, Hesk D, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007;322:477-85
  • Dugo L, Marzocco S, Mazzon E, et al. Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol 2004;141:979-87
  • Hansel TT, Kharitonov SA, Donnelly LE, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003;17:1298-300
  • Barnes PJ. Cytokine modulators as novel therapies for airway disease. Eur Respir J 2001;18:67s-77s
  • Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 2004;4:23-33
  • Onoue S, Hashimoto N, Yamada S. Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins. Expert Opin Ther Patents 2008;18:429-42
  • van der Palen J, Klein JJ, van Herwaarden CL et al. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034-7
  • Rau JL. Practical problems with aerosol therapy in COPD. Respir Care 2006;51:158-72
  • Corden ZM, Bosley CM, Rees PJ, et al. Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. Chest 1997;112:1278-82
  • Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005;50:1360-74; discussion 74-5
  • Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50:1313-21; discussion 21-2
  • Pickering H, Pitcairn GR, Hirst PH, et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000;22:1483-93
  • Kohler D. Novolizer: the new technology for the management of asthma therapy. Curr Opin Pulm Med 2003;9(Suppl 1):S11-6
  • Atkins PJ. Dry powder inhalers: an overview. Respir Care 2005;50:1304-12; discussion 12
  • Dhand R. Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients. Respir Care 2005;50:1331-4; discussion 44-5
  • Newman SP. Therapeutic aerosols, Butterworths, London, 1984
  • Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci 1971;60:1559-64
  • Dahl R, Backer V, Ollgaard B, et al. Assessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med 2003;97:1126-33
  • Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1:67-86
  • Ikegami K, Kawashima Y, Takeuchi H, et al. Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler by polymorphic transformation to needle-like crystals (beta-form). Pharm Res 2002;19:1439-45
  • Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209
  • Pover GM, Langdon CG, Jones SR, et al. Evaluation of a breath operated powder inhaler. J Int Med Res 1988;16:201-3
  • Villax P, Brito V, Steckel H. Development and performance of a new simple dry powder inhaler operating at low airflow eates, Davis Horwood International, Raleigh, NC, 2002
  • Han R, Papadopoulos G, Greenspan B. Investigation of powder dispersion inside a SPIROS dry powder inhaler using particle image velocimetry. Powd Technol 2002;125:266-78
  • Parry-Billings M, Boyes R, Clisby L, et al. Design, development and performance of a multidose dry powder inhaler. Pharm Technol 2000;12:38-45
  • Dahl R, Creemers JP, Van Noord J, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004;71:126-33
  • Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988;5:506-8
  • Fan B, Yang T, Keaton D. Application of computer modeling in the design and development of the new mometasone furoate dry powder inhaler (F-dpi) nozzle. Serentec Press, Raleigh, 2000
  • Meakin BJ, Ganderton D, Panza I, et al. The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med 1998;11:143-52
  • Keating GM, Faulds D. Airmax: a multi-dose dry powder inhaler. Drugs 2002;62:1887-95; discussion 96-7
  • de Boer AH, Gjaltema D, Hagedoorn P, et al. Comparative in vitro performance evaluation of the Novopulmon 200 Novolizer and Budesonid-ratiopharm Jethaler: two novel budesonide dry powder inhalers. Pharmazie 2004;59:692-9
  • Seppala OR, Aalto E, Annila I, et al. The efficacy of a new salbutamol metered-dose powder inhaler in comparison with two other inhaler devices. Respir Med 2001;95:949-53
  • Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005;50:367-82
  • Byron PR. Aerosol formulation, generation, and delivery using non-metered and metered systems, CRC Press, Inc., Boca Raton, FL, 1990
  • Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 2000;45:652-66
  • Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99
  • Chrystyn H. Is total particle dose more important than particle distribution? Respir Med 1997;91:(Suppl A):17-9
  • Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care 2005;50:1209-27
  • Thibert R, Parry-Billings M, Shott M. Clickhaler dry powder inhaler: focussed in vitro proof of principle evaluation of a new chemical entity for asthma. Int J Pharm 2002;239:149-56
  • de Boer AH, Hagedoorn P, Gjaltema D, et al. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. Int J Pharm 2006;310:81-9
  • Endo K, Amikawa S, Matsumoto A, et al. Erythritol-based dry powder of glucagon for pulmonary administration. Int J Pharm 2005;290:63-71
  • Louey MD, Stewart PJ. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm Res 2002;19:1524-31
  • Larhrib H, Martin GP, Marriott C, et al. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm 2003;257:283-96
  • Chan HK, Clark A, Gonda I, et al. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 1997;14:431-7
  • Staniforth JN. Pre-formulation aspects of dry powder aerosols, Interpharm Press, Buffalo Grove, 1996
  • Patton JS. Deep-lung delivery of therapeutic proteins. Chemtech 1997;27:34-8
  • Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1868-71
  • Bot AI, Tarara TE, Smith DJ, et al. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 2000;17:275-83
  • Blair J, Mao L, Hodgers E. Modification of the pulmonary absorption of cyclosporin using SoliDose technology, Serentec Press, Raleigh, 2000
  • Wilson BR, Grant MI, Steiner SS, et al. Technospheres for pulmonary and nasal applications, Davis Horwood, Raleigh, 2002
  • Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2005;62:1359-64
  • Li HY, Birchall J. Chitosan-modified dry powder formulations for pulmonary gene delivery. Pharm Res 2006;23:941-50
  • Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech 2005;6:E482-6
  • Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 2004;24:93-4
  • Vyas SP, Kannan ME, Jain S, et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269:37-49
  • Ostrander KD, Hovey DC, Knapp DA, et al. Potential delivery of advantages of spray-dried nanocrystal colloidal budesonide with Clickhaler, Serentec Press, Raleigh, 2000
  • Wollmer P, Backstrom K, Zhao H, et al. Surface active agents as enhancers of alveolar absorption. Pharm Res 2000;17:38-41
  • Khuller GK, Kapur M, Sharma S. Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des 2004;10:3263-74
  • Sivadas N, O'Rourke D, Tobin A, et al. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm 2008;358:159-67
  • Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21:2475-90
  • O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000;17:955-61
  • Pandey R, Khuller GK. Polymer based drug delivery systems for mycobacterial infections. Curr Drug Deliv 2004;1:195-201
  • Rao GC, Kumar MS, Mathivanan N, et al. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 2004;59:5-9
  • Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002;19:189-94
  • Daviskas E, Anderson SD, Gonda I, et al. Changes in mucociliary clearance during and after isocapnic hyperventilation in asthmatic and healthy subjects. Eur Respir J 1995;8:742-51
  • Dolovich MB, Jordana M, Newhouse MT. Methodologic considerations in mucociliary clearance and lung epithelial absorption measurements. Eur J Nucl Med 1987;13(Suppl):S45-52
  • Smaldone GC, Foster WM, O'Riordan TG, et al. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993;103:1390-6
  • Matilainen L, Jarvinen K, Toropainen T, et al. In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int J Pharm 2006;318:41-8
  • Onoue S, Sato H, Kawabata Y, et al. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release. In press

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.